Malignant pleural mesothelioma (MPM) is a rare tumour but with increasing incidence and a
poor prognosis. In 2008, the European Respiratory Society/European Society of Thoracic …

Objective: Treatment of malignant pleural mesothelioma (MPM) remains disappointing,
although recent reports suggest that multimodality therapy including surgery may provide a …

The incidence of malignant pleural mesothelioma (MPM) has risen for some decades and is
expected to peak between 2010 and 2020. Up to now, no single treatment has been proven …

Management of malignant pleural mesothelioma (MPM) remains a clinical challenge and
the incidence of the disease will continue to increase worldwide. Several aspects of …

Abstract Background and Objectives: Malignant pleural mesothelioma (MPM) is an asbestos-
related disease of the pleura with a survival time without treatment ranging from 4 to 12 …

The European Organisation for Research and Treatment of Cancer (EORTC; protocol
08031) phase II trial investigated the feasibility of trimodality therapy consisting of induction …

Malignant pleural mesothelioma: recent developments : Current Opinion in Oncology Malignant
pleural mesothelioma: recent developments : Current Opinion in Oncology Log in or Register …

Introduction Most studies describing the natural history and prognostic factors for malignant
pleural mesothelioma antedate accurate pathologic diagnosis, staging by computed …

Malignant pleural mesothelioma (MPM) is a rare cancer originated from pleural mesothelial
cells. MPM has been associated with long-term exposure to asbestos. The prognosis of …

Malignant mesothelioma is an insidious neoplasm arising from the mesothelial surfaces of
the pleural and peritoneal cavities, the pericardium, or the tunica vaginalis. A total of 80% of …